Answers are grounded in this paper and cite their sources.
Objective To evaluate the efficacy and safety of FcRn inhibitors compared with placebo or standard therapy in adults with generalized myasthenia gravis. Background Generalized myasthenia gravis is an antibody-mediated autoimmune disorder characterized by fluctuating skeletal muscle weakness. Current therapies may be limited by inadequate response or adverse effects. FcRn inhibitors are novel agents that reduce pathogenic IgG by blocking neonatal Fc receptor–mediated recycling. Design/Methods A systematic search of Embase, Cochrane, MEDLINE, and ClinicalTrials.gov was conducted for studies published up to April 2026. Randomized controlled trials and observational studies involving adults with generalized myasthenia gravis treated with FcRn inhibitors versus placebo or standard therapy were included. Outcomes included changes in MG-ADL and QMG scores, as well as safety endpoints. Risk of bias was assessed using RoB 2 and ROBINS-I. Random-effects meta-analysis was performed using R (version 4.5.3). Results Of 712 identified studies, five were included (4 RCTs, 1 observational; N=581). Pooled analysis showed no statistically significant difference in MG-ADL scores (MD −0.94, 95% CI −2.45 to 0.57; p=0.22; I 2 =91%) or QMG scores (MD −1.74, 95% CI −7.27 to 3.79; p=0.31; I 2 =90%). However, both outcomes demonstrated a consistent trend favoring FcRn inhibitors, with substantial heterogeneity. Safety outcomes suggested that FcRn inhibitors were well tolerated, with no significant safety concerns. Conclusions FcRn inhibitors were well tolerated and showed a trend toward clinical improvement, although results were not statistically significant and were limited by high heterogeneity and small sample size. Larger randomized controlled trials are needed to confirm their efficacy in generalized myasthenia gravis.
No takes yet. Share an insight, caveat, or question.
Somarouthu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: